Clinical Trials

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT04004442 2026-03-13

COAXIN

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07460245 2026-03-10

AVESEC

Phase 2 Not yet recruiting

144 enrolled

Carcinoma, Transitional Cell

NCT01616875 2026-03-06

Bristol Bladder Trial

Phase 2 Completed

28 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07452432 2026-03-05

Korean Prospective Upper Tract Urothelial Carcinoma Cohort

300 enrolled

Carcinoma, Transitional Cell

NCT05321316 2026-03-04

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

20 enrolled

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

10 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06040762 2026-03-02

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial

128 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07441499 2026-03-02

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

300 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Transitional Cell, Neoplasms

NCT07439120 2026-02-27

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

10 enrolled

Carcinoma, Transitional Cell

NCT06657157 2026-02-24

P-EVOLUTION

80 enrolled

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT03252938 2026-02-19

INSIGHT

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

12 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05868265 2026-02-17

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

24 enrolled

Carcinoma, Transitional Cell

NCT06138561 2026-02-17

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

180 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06724159 2026-02-17

SOGUG-PRINCIS

500 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT07234968 2026-02-17

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

70 enrolled

Phase NA Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urinary Tract Infections

NCT07413523 2026-02-17

ASTRA

44 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04459273 2026-02-05

FAPI PET RDRC

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

26 enrolled

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT07390617 2026-02-05

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

50 enrolled

Carcinoma, Transitional Cell

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

30 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Carcinoma, Transitional Cell

NCT04623502 2026-01-28

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

600 enrolled

Phase EARLY_PHASE1 Active not recruiting

Hereditary leiomyomatosis and renal cell cancer, Fumaric aciduria, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Kidney Neoplasms, Adenocarcinoma, Clear Cell

NCT04018053 2026-01-27

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

16 enrolled 3 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05154994 2026-01-27

RESOLVE

9 enrolled

Carcinoma, Transitional Cell

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

9 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07339878 2026-01-14

FLORAL

50 enrolled

Carcinoma, Transitional Cell

NCT07334314 2026-01-12

OUAF

340 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Transitional Cell

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

54 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05562791 2026-01-07

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Phase 1 Recruiting

20 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT06120374 2025-12-30

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

178 enrolled

Carcinoma, Transitional Cell

NCT07285044 2025-12-22

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidPlasma cellThoracic

27 enrolled

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT07241793 2025-12-18

TRAIN-UC-01

96 enrolled

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT00756639 2025-12-17

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

31 enrolled

CNSGenitourinary

Adenocarcinoma, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Phase 1/2 Active not recruiting

46 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06129084 2025-12-15

A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

Active not recruiting

260 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05768347 2025-12-04

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

9 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06265285 2025-12-04

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

50 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT03575013 2025-12-03

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

Phase 1 Completed

21 enrolled

Carcinoma, Transitional Cell

NCT04388852 2025-11-21

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

65 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT06218433 2025-11-18

Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)

GastrointestinalGenitourinary

200 enrolled

Urogenital Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Colorectal Neoplasms, Hereditary Nonpolyposis, Neoplastic Syndromes, Hereditary

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

15 enrolled 17 charts

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

57 enrolled

Carcinoma, Transitional Cell

NCT04724018 2025-11-04

Sacituzumab Govitecan Plus EV in Metastatic UC

Phase 1/2 Recruiting

106 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06396533 2025-10-31

INSITE

92 enrolled

Carcinoma, Transitional Cell

NCT05923190 2025-10-29

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

70 enrolled